检索结果-南通市图书馆

在线全文

学校读者我要写书评

暂无评论

中国全面发育迟缓诊断指南

中华实用儿科临床杂志 2024年第7期39卷 481-489页

作者：国家儿童医学中心, 首都医科大学附属北京儿童医院保健中心北京市儿科专业质量控制和改进中心中国妇幼保健协会儿童脑科学与脑健康促进专业委员会北京健康文化促进会儿童青少年健康发展专业委员会妇幼健康研究会孤独症防治研究专业委员会中华医学会儿科学分会发育行为学组《中华实用儿科临床杂志》编辑委员会国家儿童医学中心北京市儿科专业质量控制和改进中心中国妇幼保健协会儿童脑科学与脑健康促进专业委员会北京健康文化促进会儿童青少年健康发展专业委员会妇幼健康研究会孤独症防治研究专业委员会中华医学会儿科学分会发育行为学组《中华实用儿科临床杂志》编辑委员会

为规范我国全面发育迟缓(GDD)的诊断, 急需将临床经验与循证医学相结合, 建立适合我国人群的GDD临床诊断指南。本指南针对GDD诊断的9个临床问题, 系统检索截至2022年7月的国内外相关文献, 采用牛津循证医学证据等级(OCEBM)对证据水平和... 详细信息

为规范我国全面发育迟缓(GDD)的诊断, 急需将临床经验与循证医学相结合, 建立适合我国人群的GDD临床诊断指南。本指南针对GDD诊断的9个临床问题, 系统检索截至2022年7月的国内外相关文献, 采用牛津循证医学证据等级(OCEBM)对证据水平和推荐意见的推荐等级进行分级, 最终形成相应推荐意见。

关键词：全面发育迟缓诊断指南

Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors(2021 edition)

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Cancer Innovation 2022年第1期1卷 3-24页

作者： Professional Committee on clinical research of Oncology Drugs,Chinese Anti‐Cancer Association Expert Committee for Monitoring the clinical Application of Antitumor Drugs Breast Cancer Expert Committee of national Cancer Quality Control center| Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement center Fei Ma Binghe Xu 不详 Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China DepartmentofMedical Oncology andclinicalTrialcenter National CancerCenter/NationalClinical Research CenterforCancer/Cancer HospitalChineseAcademyofMedical Sciences andPekingUnionMedical CollegeBeijing100021China

Antibody‐drug conjugates(ADCs)are targeted biological agents composed of a cytotoxic drug linked to a monoclonal antibody through a *** monoclonal antibody targets tumor cells and transports small‐molecule cytotoxic drugs for specific delivery and minimal off‐target side *** is necessary for clinicians to understand the molecular characteristics and mechanisms of ***'survival mainly depends on the appropriate dose and course of treatment and also on proper management of adverse *** consensus provides a systematic review of commercially available ADCs and further discusses the clinical application and management of ADCs.

关键词： malignant tumors antibody‐drug conjugates monoclonal antibodies cytotoxic drugs safety management

2023 Chinese national clinical practice guideline on diagnosis and management of Crohn’s disease

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第14期137卷 2024 Jul 2页

作者： Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association Inflammatory Bowel Disease Quality Control center of China Xijing Hospital Air Force Medical University China Peking Union Medical College Hospital China West China Hospital Sichuan University China The First Affiliated Hospital Dalian Medical University China University of Nottingham Ningbo China GRADE Centre United Kingdom The First Affiliated Hospital Sun Yat-sen University China Sir Run Run Shaw Hospital Zhejiang University School of Medicine China Peking University People's Hospital China The Second Affiliated Hospital Zhejiang University School of Medicine China Renmin Hospital Wuhan University China Chinese PLA General Hospital China The First Affiliated Hospital Naval Medical University China The Sixth Affiliated Hospital Sun Yat-sen University China The First Affiliated Hospital Anhui Medical University China Zhongshan Hospital Xiamen University China Zhongnan Hospital Wuhan University China The First Hospital of Shanxi Medical University China The Eighth Affiliated Hospital Sun Yat-sen University China Peking University Third Hospital China Peking University First Hospital China Qilu Hospital Shandong University China General Hospital of Eastern Theater Command China Xiangya Hospital Central South University China The Tenth People's Hospital Tongji University China The First Affiliated Hospital Kunming Medical University China Shanghai Pudong New District Zhoupu Hospital China Ruijin Hospital Shanghai Jiao Tong University School of Medicine China Tongji Medical College Huazhong University of Science and Technology China General Hospital of Nanjing Military Command China The Third Xiangya Hospital Central South University China Daping Hospital Chongqing China The Second Xiangya Hospital Central South University China Jiangsu Provincial People's Hospital China The Second Hospital of Hebei Medical University China Nanjing Drum Tower Hospital China Nanfan Hospital Southern Medical University China GRADE center University of Nottingham Ningbo China The Fifth Affiliated Hospital Zhengzhou University

The role of Chinese expert consensus in standardization and improvement of the clinical diagnosis and treatment of inflammatory bowel disease (IBD) is self-evident. As clinical and basic research in China becomes standardized under a better understanding of IBD, more data on Chinese patients have become available to develop a consensus and guideline. This guideline, collaboratively developed by the IBD Group, Chinese Society of Gastroenterology, incorporates the latest international consensus statements,[1-7] domestic research findings, and practical considerations, as an update based on the 2018 Chinese consensus on IBD management.[8] The IBD guideline consists of two parts: ulcerative colitis (UC) and Crohn's disease, and this manuscript presented the UC part. The evidence used in this guideline was collected and analyzed by the standard of guideline, and the contents were organized as problem statements, for clarity. The formulation of this guideline aimed to reflect the latest progress in IBD, providing comprehensive and valuable guidance for the clinical management of IBD.

关键词：

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer research 2024年第3期36卷 240-256页

作者： Zaiwei Song Dan Jiang Lingling Yu Yixuan Chen Daobin Zhou Yue Li Depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao the Steering Committee,the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of Chinese Pharmaceutical Association(CPA) Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association(CPA) Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society(CPS) Expert Committee on Lymphoma of Chinese Society of clinical Oncology(CSCO) Expert Committee on Leukemia of Chinese Society of clinical Oncology(CSCO) Society of Integrative Cardio-Oncology of China Anti-Cancer Association(CACA) Chinese Society of Hematology of Chinese Medical Association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits Medicine Exchange Association(SMEA) Department of Pharmacy Peking University Third HospitalBeijing 100191China Institute for Drug Evaluation Peking University Health Science CenterBeijing 100191China Therapeutic Drug Monitoring and clinical Toxicology center Peking UniversityBeijing 100191China Department of Pharmacy Administration and clinical Pharmacy School of Pharmaceutical SciencesPeking UniversityBeijing 100191China Department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100005China Department of Cardiology the First Affiliated HospitalHarbin Medical UniversityHarbin 150001China Department of Hematology the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan UniversityChengdu 610041China Department of Pharmacy the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Hematology and Oncology Harbin Institute of Hematology and OncologyHarbin 150010China Key Laboratory of Carcinogenesis and Translational research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Department of Hematology Peking University Third HospitalBeijing 100191China 不详

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell ***,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased *** evidence-based expert consensus was formulated using an evidence-based approach and the Delphi *** Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,*** consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special *** multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

关键词： Consensus BTK inhibitors safety adverse drug events drug-drug interactions

中国非儿童癌症患者脓毒血症流行情况及地域分布:一项全国横断面研究

在线全文

学校读者我要写书评

暂无评论

Science Bulletin 2024年第11期69卷 1637-1641页

作者：陆斌胥洋李娜周月阳马旭东陈燕董润周翔代敏陈宏达翁利杜斌中国国家重症医学质控中心和中国重症医学临床试验组 center for Prevention and Early Intervention National Infrastructures for Translational MedicineInstitute of Clinical MedicinePeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Department of Cancer Epidemiology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Pharmacy Administration and clinical Pharmacy School of Pharmaceutical SciencesPeking University Health Science CenterBeijing 100191China Department of Medical Epidemiology and Biostatistics Karolinska InstitutetStockholm 17177Sweden Department of Medical Administration National Health Commission of the People’s Republic of ChinaBeijing 100044China Medical Intensive Care Unit State Key Laboratory of Complex Severe and Rare DiseasesPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Intensive Care Unit State Key Laboratory of Complex Severe and Rare DiseasesPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China 不详

Cancer poses a major public health burden worldwide,with approximately 18,094,716 newly diagnosed cases and 9,894,402 cancer-related deaths in 2020[1].Infections such as sepsis are among the leading causes of death in... 详细信息

关键词：脓毒血症横断面研究 death 地域分布

体检人群幽门螺杆菌血清学检测专家共识(2022年)

在线全文

学校读者我要写书评

暂无评论

健康体检与管理 2022年第4期3卷 329-335,349页

作者：中华医学会健康管理学分会国家消化病临床医学研究中心(上海) 中华医学会消化病学分会幽门螺杆菌学组《健康体检与管理》杂志编委会中国医师协会医师健康管理与医师健康保险专业委员会郭清曾强周丽雅刘玉萍杜奕奇宋震亚陈刚张志勉范竹萍朱惠云不详浙江中医药大学健康管理研究所解放军总医院第二医学中心健康管理研究院北京大学第三医院消化内科四川省人民医院健康管理中心海军军医大学第一附属医院消化内科浙江大学医学院附属第二医院健康管理中心《健康体检与管理》杂志社山东大学齐鲁医院健康管理中心上海交通大学医学院附属仁济医院消化内科

幽门螺杆菌(Hp)感染与消化道疾病尤其是胃癌的发生密切相关,常规体检中包含Hp检测项目显得尤为重要。在众多指南共识推荐的Hp非侵入性检测方法中,血清学Hp抗体检测有助于判断Hp感染史和特定情况下的现症感染,与尿素呼气试验结合可进一... 详细信息

幽门螺杆菌(Hp)感染与消化道疾病尤其是胃癌的发生密切相关,常规体检中包含Hp检测项目显得尤为重要。在众多指南共识推荐的Hp非侵入性检测方法中,血清学Hp抗体检测有助于判断Hp感染史和特定情况下的现症感染,与尿素呼气试验结合可进一步提高现症感染诊断准确率,并可通过检测细胞毒素相关蛋白A(CagA)和空泡毒素A(VacA)抗体判断Hp毒力,为精准根除Hp提供临床依据。目前国内医疗机构关于Hp血清学检测应用及检测结果解读缺乏统一规范,本共识旨在指导标准化的Hp血清学检测流程,推进血清学检测在体检人群中的应用,从而助力Hp感染的精准防控和早期胃癌的筛查。

关键词：体检人群幽门螺杆菌血清抗体检测毒力分型 CagA VacA

在线全文

学校读者我要写书评

暂无评论

中国大动脉炎诊疗指南(2023)

中华内科杂志 2024年第2期63卷 132-152页

作者：国家皮肤与免疫疾病临床医学研究中心(北京协和医院) 中国医师协会风湿免疫专科医师分会血管炎学组海峡两岸医药卫生交流协会风湿免疫病学专业委员会血管炎学组中国康复医学会风湿免疫病康复专业委员会田新平曾小峰不详中国医学科学院、北京协和医学院、北京协和医院风湿免疫科北京100730 中国医学科学院、北京协和医学院、国家皮肤与免疫疾病临床医学研究中心、疑难重症及罕见病国家重点实验室、风湿免疫病学教育部重点实验室北京100730

大动脉炎(TAK)是一种累及主动脉及其一级分支动脉的系统性血管炎,可导致受累动脉管壁增厚、管腔狭窄或动脉瘤形成,造成所供应脏器的缺血改变。临床诊治极具挑战性。为提高TAK的诊疗水平,规范我国TAK的诊治,由国家皮肤与免疫疾病临床医... 详细信息

大动脉炎(TAK)是一种累及主动脉及其一级分支动脉的系统性血管炎,可导致受累动脉管壁增厚、管腔狭窄或动脉瘤形成,造成所供应脏器的缺血改变。临床诊治极具挑战性。为提高TAK的诊疗水平,规范我国TAK的诊治,由国家皮肤与免疫疾病临床医学研究中心牵头,基于循证医学证据制定了以临床问题为导向的我国TAK诊疗指南,共对11个TAK诊治中的重要临床问题,基于最新的研究证据及专家意见,结合我国临床实际,给出推荐和建议,旨在指导临床实践。

关键词：大动脉炎诊断治疗指南

在线全文

学校读者我要写书评

暂无评论

花粉-食物过敏综合征诊断及管理专家共识

中华预防医学杂志 2024年第6期58卷 719-734页

作者：中华医学会变态反应学分会过敏原特异性诊断学组福棠儿童医学发展研究中心过敏(变态)反应学科规范化建设研究组北京慢性病防治与健康教育研究会变态反应学专业委员会中国老年保健协会过敏性疾病分会关凯向莉姜楠楠李丽莎不详中国医学科学院北京协和医学院北京协和医院变态(过敏)反应科过敏性疾病精准诊疗研究北京市重点实验室国家皮肤与免疫疾病临床医学研究中心北京100730 国家儿童医学中心首都医科大学附属北京儿童医院过敏反应科儿童重大疾病研究教育部重点实验室国家呼吸系统疾病临床医学研究中心北京100045

花粉-食物过敏综合征(pollen-food allergy syndrome,PFAS)是发生在花粉过敏个体的食物过敏反应。近年来,花粉过敏发病率逐年升高且呈现低龄化趋势,PFAS在国内也逐渐受到关注。PFAS的临床特征具有明显的地域差异及异质性。目前,国内对P... 详细信息

花粉-食物过敏综合征(pollen-food allergy syndrome,PFAS)是发生在花粉过敏个体的食物过敏反应。近年来,花粉过敏发病率逐年升高且呈现低龄化趋势,PFAS在国内也逐渐受到关注。PFAS的临床特征具有明显的地域差异及异质性。目前,国内对PFAS诊断手段有限,认识不足,尚无可供临床使用的诊断标准。与原发性食物过敏的管理有所不同,PFAS管理需要同时兼顾花粉过敏和食物过敏,管理具有特殊性和复杂性,医生在临床实践中管理存在差异。本共识基于目前国内外现有的指南和我国相关研究证据,制定了诊断标准和管理流程图,旨在规范我国PFAS诊治流程,提高诊疗水平,指导变态反应科医师、相关专业医师和全科医师正确认识、诊断及规范管理PFAS。

关键词：食物过敏花粉过敏专家共识花粉-食物过敏综合征口腔过敏综合征

中国生殖支原体感染诊疗专家共识(2024)

在线全文

学校读者我要写书评

暂无评论

中华皮肤科杂志 2024年第3期57卷 201-208页

作者：中国医学科学院皮肤病医院中国疾病预防控制中心性病控制中心中华医学会皮肤性病学分会性病学组中国康复医学会皮肤病康复专业委员会苏晓红王千秋刘全忠不详中国医学科学院皮肤病医院天津医科大学总医院

生殖支原体可引起尿道炎、宫颈炎和盆腔炎等泌尿生殖道感染,并且与早产相关。因培养困难,诊断依赖于核酸检测,其耐药性增加导致临床治疗面临巨大挑战。中国医学科学院皮肤病医院、中国疾病与预防控制中心性病控制中心、中华医学会皮肤... 详细信息

生殖支原体可引起尿道炎、宫颈炎和盆腔炎等泌尿生殖道感染,并且与早产相关。因培养困难,诊断依赖于核酸检测,其耐药性增加导致临床治疗面临巨大挑战。中国医学科学院皮肤病医院、中国疾病与预防控制中心性病控制中心、中华医学会皮肤性病学分会和中国康复医学会皮肤病康复专业委员会组织国内有关专家依据国际最新生殖支原体诊疗指南及国内外研究进展,围绕生殖支原体感染病原学、流行病学、临床表现、实验室检测、诊断与治疗、随访和判愈、性伴管理、预防等内容进行充分讨论,形成此共识,旨在提高我国临床医师对生殖支原体感染的认识和诊疗水平。

关键词：生殖器支原体感染性传播疾病诊断治疗共识